Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer.
Esmo Open
Wolf, J J; Helland, Å Å; Oh, I-J IJ; Migliorino, M R MR; Dziadziuszko, R R; Wrona, A A; de Castro, J J; Mazieres, J J; Griesinger, F F; Chlistalla, M M; Cardona, A A; Ruf, T T; Trunzer, K K; Smoljanovic, V V; Novello, S S
Final efficacy and safety data, and exploratory molecular profiling from the phase III ALUR study of alectinib versus chemotherapy in crizotinib-pretreated ALK-positive non-small-cell lung cancer.
Esmo Open
Wolf, J J; Helland, Å Å; Oh, I-J IJ; Migliorino, M R MR; Dziadziuszko, R R; Wrona, A A; de Castro, J J; Mazieres, J J; Griesinger, F F; Chlistalla, M M; Cardona, A A; Ruf, T T; Trunzer, K K; Smoljanovic, V V; Novello, S S
mTOR Signaling and SREBP Activity Increase FADS2 Expression and Can Activate Sapienate Biosynthesis.
Cell Reports
Triki, Mouna M; Rinaldi, Gianmarco G; Planque, Melanie M; Broekaert, Dorien D; Winkelkotte, Alina M AM; Maier, Carina R CR; Janaki Raman, Sudha S; Vandekeere, Anke A; Van Elsen, Joke J; Orth, Martin F MF; Grünewald, Thomas G P TGP; Schulze, Almut A; Fendt, Sarah-Maria SM
Machine Learning Detects Pan-cancer Ras Pathway Activation in The Cancer Genome Atlas.
Cell Reports
Way, Gregory P GP; Sanchez-Vega, Francisco F; La, Konnor K; Armenia, Joshua J; Chatila, Walid K WK; Luna, Augustin A; Sander, Chris C; Cherniack, Andrew D AD; Mina, Marco M; Ciriello, Giovanni G; Schultz, Nikolaus N; , ; Sanchez, Yolanda Y; Greene, Casey S CS